Anti–coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin

Xingyue Qin¹ | Chen Huang² | Ka Wu³ | Yu Li⁴ | Xiao Liang⁴ | Min Su⁴ | Rong Li⁴

Abstract

The present study aimed to uncover the pharmacological function and underlying mechanism of puerarin as a potential treatment for COVID-19, using an in silico methodology, including network pharmacology and molecular docking. The pivotal targets of puerarin to treat COVID-19 were identified and included the epidermal growth factor receptor (EGFR), tumour necrosis factor (TNF), tumour protein p53 (TP53), caspase 3 (CASP3), RELA proto-oncogene (RELA), Fos proto-oncogene (FOS), caspase 8 (CASP8), prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin 2 (IL2), protein kinase CB (PRKCB), B cell lymphoma/leukaemia gene-2 (BCL2), protein kinase CA (PRKCA), nitric oxide synthase 3 (NOS3) and peroxisome proliferator–activated receptor gamma (PPARG). Functionally, the anti–COVID-19 action of puerarin was associated with the suppression of oxidative stress and inflammatory cascades, and cell apoptosis. The signalling pathways of puerarin to treat COVID-19 included modulation of the pathways of apoptosis, IL-17 signalling, mitogen-activated protein kinase (MAPK) signalling and TNF signalling. Molecular docking data illustrated the binding capacity of puerarin with COVID-19 and the effective anti–COVID-19 activity of puerarin. Taken together, our current network pharmacology–based findings revealed the pharmacological role of puerarin in the treatment of COVID-19. Furthermore, the bioinformatic findings elucidated that some of these pivotal targets might serve as potential molecular markers for detecting COVID-19.

KEYWORDS
COVID-19, molecular docking, network pharmacology, puerarin, targets
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogenic agent responsible for causing COVID-19, a severe and life-threatening epidemic disease that has led to a massive economic burden and increasing death toll in the world.1 As an evolving epidemic, COVID-19 is rapidly growing and spreading in several countries, including the United States, Brazil and India.2 Epidemiological evidence suggests that the trend of COVID-19 infection is difficult to control because of insufficient management against COVID-19, characterized by huge rates of cases in different countries.3 In the United States, COVID-19 has already affected millions of people and is characterized by an increasing incidence and death rate.4 Pathologically, the main clinical characteristics of COVID-19 are related to inflammation, cytokine storms, immunodeficiency and infection.5 In clinical management against COVID-19, the common therapy may involve supportive care,6 such as breathering assistance, as the development of an effective drug and new vaccine is still ongoing.7 Traditionally, Pueraria montana (Gegen) is found to relieve muscle fever, neutralize alcoholism-related hypoglycaemic and hypolipemic actions.8 Puerarin, rich in Pueraria montana, exerts evident pharmacological benefits, such as preventing coronary heart disease and anti-alcoholism and anti-diabetic effects.9 In previous preclinical studies, puerarin was found to have potent hepatoprotection, neuroprotection and anti-dysmetabolism effects.10-13 It has been reported that puerarin may function as a natural amoebicidal agent to manage Acanthamoeba-induced pneumonia.14 In addition, puerarin plays an important role in anti-inflammatory action, including prevention of acute lung injury by reducing inflammatory stress.15,16 However, there is currently no specific drug for the treatment of COVID-19. Although some antiviral drugs and traditional Chinese medicines have been used in the clinical treatment of COVID-19, its therapeutic effectiveness is not clear. Collectively, we aimed to determine and identify the curative effect of puerarin in the treatment of COVID-19 and the therapeutic mechanisms involved. It is of great interest to use bioinformatic and computational methods based on network pharmacology to unveil the potential agent to treat illness.17 Using the network pharmacology strategy, we have reported the pharmacological targets and molecular pathways of bioactive agents against complex diseases.18,19 Thus, in this bioinformatic report, we intended to reveal the component-target-pathway network and pharmacological mechanism of puerarin in the treatment of COVID-19.

2 | MATERIALS AND METHODS

2.1 | Screening of the target of puerarin in the treatment of COVID-19

The total established target genes of puerarin were selected using the effective tools of traditional Chinese medicine systems pharmacology (TCMSP), Swiss Target Prediction and SuperPred. Meanwhile, other COVID-19-nosopoietic genes were acquired using the gene-disease associations (DisGeNET) and GeneCards databases. Additionally, these acknowledged genes of puerarin and COVID-19 were mapped prior to emendation using the UniProt tool. After functional enrichment analysis using FunRich software, all anti-COVID-19 biotargets of puerarin were screened and identified, as reported elsewhere.20,21

2.2 | Screening of pivotal targets of puerarin to treat COVID-19 and construction of PPI network

The total acknowledged targets of puerarin and COVID-19 were used to further determine and construct a functional protein association network via the STRING database following a specific algorithm. In addition, these merged targets of puerarin and COVID-19 were used to construct a network of protein-protein interactions (PPI) using the Cytoscape software. As revealed by topological parameters using the Network Analyzer tool, the pivotal targets of puerarin to treat COVID-19 were identified and visualized.22,23

2.3 | Enrichment analyses in biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of intersection targets

Using the R language packages, such as ‘ClusterProfiler’, ‘ReactomePA’, ‘org.Hs.eg.Db’ and ‘GOplot’ in the R language (3.6.1), the enrichment analysis and visualization of the biological process and KEGG pathways of the intersection targets were performed and obtained accordingly. Moreover, the information on gene annotation resulted from ‘org.Hs.eg.Db’, p-value cut-off = 0.05, q-value cut-off = 0.05 for enrichment prior to plotting the corresponding bubble chart, histogram and Circos circle chart.24,25

2.4 | Molecular docking analysis

Using the chemical-protein binding method, the pivotal targets were screened out and identified for puerarin-based molecular docking analysis. After searching for specific proteins through the PDB database, SR84 protein was selected to dock with the puerarin compound. The ChemBio3D Draw in Chem Bio Office 2010 software was used to conduct the three-dimensional structure of puerarin before docking the molecular structures using AutoDock Vina software. The rationality of the docking parameter setting was assessed according to the root-mean-square deviation (RMSD) of the ligand molecule. The RMSD ≤ 4 Å was the threshold for the conformation of the ligand molecule.26,27
3 | RESULTS

3.1 | Findings of putative genes of puerarin and COVID-19

As revealed in Figure 1, 393 COVID-19–morbid genes were selected and detected. A total of 138 putative genes of puerarin were specified following the databases. As shown in the Venn diagram, 34 shared genes of puerarin to treat COVID-19 were screened and identified. Furthermore, these mapped genes were reused to plot an interaction network.

3.2 | Identification of all pivotal targets

All the mapped intersection proteins were input into Cytoscape 3.7.1 software to calculate the topological parameters of the interaction network of targets and functionally related proteins of puerarin in the treatment of COVID-19. The algorithm from the network freedom median degree of 6.129 and freedom maximum degree of 15 was used to identify the pivotal targets of puerarin to treat COVID-19. Therefore, the pivotal target screening condition range was set to 7-15, and finally, 14 pivotal targets were obtained. These genes included EGFR, TNF, TP53, CASP3, RELA, FOS, CASP8, PTGS2, IL2, PRKCB, BCL2, PRKCA, NOS3 and PPARG, as shown in Figure 2 and Table S1.

3.3 | Enrichment findings of pivotal targets

Following the assays using R language-related packages, the anti-COVID-19 molecular pathways from puerarin-achieved pivotal targets...
FIGURE 3  All top biological processes of puerarin to treat COVID-19 based on enrichment analyses were revealed and visualized. These main functions of puerarin-anti–COVID-19 were associated with regulation of different BPs of coronavirus, as detailed in bar diagram (A), circle diagram (B)
All top molecular pathways of puerarin to treat COVID-19 from enrichment analyses were uncovered and visualized. These key KEGG pathways of puerarin-anti–COVID-19 were related to modulation of respective signalling pathways of coronavirus, as detailed in bar diagram (A) and circle diagram (B).
were determined and revealed accordingly. Results showed that puerarin treatment of COVID-19 targets related biological processes mainly involved in response to oxidative stress, response to lipopolysaccharide, response to molecule of bacterial origin, response to steroid hormone, extrinsic apoptotic signalling pathway, response to reactive oxygen species, response to UV, response to glucocorticoid, cellular response to oxidative stress, response to corticosteroid, response to light stimulus, cellular response to external stimulus, response to osmotic stress, response to mechanical stimulus, positive regulation of neuron death, regulation of apoptotic signalling pathway, myeloid cell differentiation, negative regulation of apoptotic signalling pathway, negative regulation of extrinsic apoptotic signalling pathway and reproductive structure development (Figure 3A, Table S2). Meanwhile, the related cell components of puerarin in the treatment of COVID-19 target were mainly related to membrane raft, membrane microdomain, membrane region, transcription factor complex, RNA polymerase II transcription factor complex, caveola, plasma membrane raft and mitochondrial outer membrane. In addition, the molecular functions of puerarin in the treatment of COVID-19 targets mainly involved ubiquitin protein ligase binding, protease binding, ubiquitin-like protein ligase binding, protein phosphatase binding, tumour necrosis factor receptor superfamily binding, phosphatase binding, activating transcription factor binding, cytokine receptor binding, cysteine-type endopeptidase activity involved in the apoptotic process, protein kinase C activity, death receptor binding, histone kinase activity, RNA polymerase II transcription factor binding, tumour necrosis factor receptor binding, protein phosphatase 2A binding, pivotal promoter sequence–specific DNA binding, actinin binding, pivotal promoter binding, protein self-association and scaffold protein binding (Figure 3B). The other 138 KEGG pathways (P-adjust < .05) of pivotal targets were identified and were mainly involved in hepatitis B, human cytomegalovirus infection, AGE-RAGE signalling pathway in diabetic complications, sphingolipid signalling pathway, human immunodeficiency virus 1 infection, apoptosis, measles, IL-17 signalling pathway, MAPK signalling pathway, HIF-1 signalling pathway, TNF signalling pathway, fluid shear stress and atherosclerosis, oxytocin signalling pathway, hepatitis C, leishmaniasis, influenza A, colorectal cancer, microRNAs in cancer, small-cell lung cancer and Kaposi sarcoma–associated herpesvirus infection (Figure 4A,B, Table S3).

3.4 Construction of network diagram

Further, the network visualization of puerarin-target-biological process (BP)-KEGG-COVID-19 was created using Cytoscape 3.7.1 software, as shown in Figure 5.
3.5 | Molecular docking findings

From the interaction diagram of the original ligand and the protein-ligand complex, the data showed the amino acid residues HIS-163 and GLU-166, where the original ligand GWS binds to the 5R84 protein. In the three-dimensional picture of puerarin, it is observed that the binding residues of hydrogen bonded with TYR-54, ASN-142, GLU-166 and GLN-189. In addition, puerarin formed hydrogen bonds with the amino acid residues TYR-54, ASN-142, GLU-166 and GLN-189 in the 5R84 protein (Figure 6). Meanwhile, the free binding energy of puerarin and 5R84 is −7.5 kcal/mol, and the binding free energy of the original ligand GWS and protein is −7.23 kcal/mol. The binding energies of puerarin and GWS were similar. These docking results indicated that puerarin had a potent interaction with 5R84 protein.

4 | DISCUSSION

In our current study, the in silico findings from the network pharmacology approach and molecular docking analysis revealed the pharmacological targets, functions and signalling pathways of puerarin-achieved anti–COVID-19 effects. In detail, all pivotal biotargets of puerarin to treat COVID-19 were identified via bioinformatic determination, including EGFR, TNF, TP53, CASP3, RELA, FOS, CASP8, PTGS2, IL2, PRKCB, BCL2, PRKCA, NOS3 and PPARG. Molecular docking data indicated that the binding capacity of puerarin with COVID-19 was significant, indicating the potential and pharmacological activities of puerarin in the treatment of COVID-19. FOS, a proto-oncogene, is considered a regulator of cell proliferation, differentiation and transformation. Overexpression of the FOS gene is also related to apoptotic cell death. Prostaglandin-endoperoxide synthase 2 (PTGS2) is a key enzyme in the production of prostaglandins, which play a significant role in inflammation, pain, fever, and blood clotting. The inhibition of PTGS2 can lead to the reduction of prostaglandins, thereby alleviating these physiological responses. Consequently, puerarin’s interaction with PTGS2 could be another potential target for understanding its anti-inflammatory effects.
synthase (PTGS) is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis when it is induced by specific stimulatory genes. Some interesting data indicate that targeting suppression of PGE2 synthesis is likely to reduce bacterial infection in mice. Protein kinase C (PKC), including PRKCB and PRKCA, is involved in diverse cellular signalling pathways, including those involved in cancer. The proteins encoded by PRKCB and PRKCA genes have been reported to be associated with numerous cellular functions, such as B cell activation, apoptosis induction and endothelial cell proliferation. NOS3 (nitric oxide synthase 3) may induce nitric oxide release for the regulation of angiogenesis and cell proliferation. Interestingly, NOS3 may functionally suppress sepsis-caused systemic inflammation and myocardial dysfunction in mice. Collectively, there is no associated investigation for the associations between FOS, PTGS, PRKCB, PRKCA, NOS3 and COVID-19. Therefore, the current in silico findings using network pharmacology uncovered all pharmacological targets, functions and signalling pathways of puerarin to treat COVID-19, marked by inhibition of cytokine-cytokineand inflammation-associated signalling pathways, such as the IL-17 signalling pathway, TNF signalling pathway, MAPK signalling pathway and HIF-1 signalling pathway. Potentially, puerarin may be a promising active compound against COVID-19. However, it needs to be confirmed by future experimental works.

5 | CONCLUSION

In silico approaches based on network pharmacology and molecular docking were used to harvest the mapped and pivotal biotargets, pharmacological functions and therapeutic mechanisms of puerarin in treatment of COVID-19. Additionally, total pivotal biotargets of puerarin to treat COVID-19 were identified, including new anti-COVID-19 targets that may comprise FOS, PTGS, PRKCB, PRKCA and NOS3.

ACKNOWLEDGEMENTS

This study is supported by the National Natural Science Foundation of China (Nos. 81560134 and 81660091) and the National Natural Science Foundation of Guangxi (Nos. 2019GXNSFBA185015 and 2018GXNSFAA281242).

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Xingyue Qin: Conceptualization (equal); Formal analysis (equal); Investigation (equal); Validation (equal); Chen Huang: Data curation (equal); Formal analysis (equal); Methodology (equal); Writing-review & editing (lead). Ka Wu: Resources (equal); Software (equal); Visualization (equal). Yu Li: Data curation (equal); Formal analysis (equal); Investigation (equal); Software (equal). Xiao Liang: Methodology (equal); Resources (equal); Software (equal). Min Su: Funding acquisition (equal); Supervision (equal); Writing-original draft (equal). Rong Li: Conceptualization (equal); Funding acquisition (equal); Project administration (equal).

DATA AVAILABILITY STATEMENT

The data that supports the findings of this study are available in the supplementary material of this article.

ORCID

Min Su https://orcid.org/0000-0002-7867-1539
Rong Li https://orcid.org/0000-0002-8210-1213

REFERENCES

1. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948.
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020;83:217-220.
3. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92:548-551.
4. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis (Berl). 2020;7:91-96.
5. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23:268-271.
6. Schijns V, Lavelle EC. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Eur J Immunol. 2020;50:932-938.
7. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infect Genet Evol. 2020;83:104327.
8. Yang L, Chen J, Lu H, et al. Pueraria lobata for diabetes mellitus: past, present and future. Am J Chin Med. 2019;47:1419-1444.
9. Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28:961-975.
10. Li R, Xu L, Liang T, Li Y, Zhang S, Duan X. Puerarin mediates hepatoprotection against CCl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. Food Chem Toxicol. 2013;52:69-75.
11. Li R, Zheng N, Liang T, He Q, Xu L. Puerarin attenuates neuronal degeneration and blocks oxidative stress to elicit a neuroprotective effect on substantia nigra injury in 6-OHDA-lesioned rats. Brain Res. 2013;1517:28-35.
12. Li R, Liang T, Xu L, Zheng N, Zhang K, Duan X. Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway. Brain Res. 2013;1523:1-9.
13. Li R, Song J, Wu W, Wu X, Su M. Puerarin exerts the protective effect against chemical induced dysmetabolism in rats. Gene. 2016;595:168-174.
14. Derda M, Hadaš E, Thiem B. Plant extracts as natural amoebicidal agents. Parasitol Res. 2009;104:705-708.
15. Wang X, Yan J, Xu X, et al. Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response. Microb Pathog. 2018;118:170-176.
16. Wang C, Yan M, Jiang H, et al. Protective effects of puerarin on acute lung and cerebrum injury induced by hypobaric hypoxia via the regulation of aquaporin (AQP) via NF-κB signaling pathway. Int Immunopharmacol. 2016;40:300-309.
17. Su M, Guo C, Liu M, Liang X, Yang B. Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology. Int Immunopharmacol. 2019;66:383-387.
18. Wu K, Wei P, Liu M, Liang X, Su M. To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. J Adv Res. 2019;20:43-50.

19. Zhou R, Wu K, Su M, Li R. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019;70:103200.

20. Li R, Guo C, Li Y, Liang X, Yang L, Huang W. Therapeutic target and molecular mechanism of vitamin C-treated pneumonia: a systematic study of network pharmacology. Food Funct. 2020;11:4765-4772.

21. Li R, Wu K, Li Y, et al. Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19. Aging (Albany NY). 2020;12:15784-15796.

22. Li R, Ma X, Song Y, et al. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019;120:11265-11273.

23. Liang Y, Zhou R, Liang X, Kong X, Yang B. Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study. Eur J Pharmacol. 2020;881:173227.

24. Li R, Guo C, Li Y, Qin Z, Huang W. Therapeutic targets and signaling mechanisms of Vitamin C activity against sepsis: a bioinformatics study. Brief Bioinform. 2020;bbaa079. https://doi.org/10.1093/bib/bbaa079.

25. Li R, Wu K, Li Y, Liang X, Lai KP, Chen J. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses. Brief Bioinform. 2020;bbaa141.

26. Nong Y, Liang Y, Liang X, Li Y, Yang B. Pharmacological targets and mechanisms of calycosin against meningitis. Aging (Albany NY). 2020;12:19468-19492.

27. Li R, Guo C, Li Y, Liang X, Su M. Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia. Chemosphere. 2021;263:128242.

28. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005;41:2449-2461.

29. Seo MJ, Oh DK. Prostaglandin synthases: molecular characterization and involvement in prostaglandin biosynthesis. Prog Lipid Res. 2017;66:50-68.

30. Dolan JM, Weinberg JB, O’Brien E, et al. Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice. Am J Physiol Lung Cell Mol Physiol. 2016;310:1111-1120.

31. Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36-52.

32. Youssef I, Ricort JM. Deciphering the role of protein kinase D1 (PKD1) in cellular proliferation. Mol Cancer Res. 2019;17:1961-1974.

33. Keilhoff G. nNOS deficiency-induced cell proliferation depletes the neurogenic reserve. Neurosci Lett. 2011;505:248-253.

34. Bougaki M, Searles RJ, Kida K, Yu J, Buys ES, Ichinose F. Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis. Shock. 2010;34:281-290.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Qin X, Huang C, Wu K, et al. Anti–coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin. J Cell Mol Med. 2021;25:677–685. https://doi.org/10.1111/jcmm.16117